Eli Lilly and Co

NYSE:LLYUnited States

Sep 25, 2024

Show headlines and story abstract

• Eli Lilly Says New Data Show Atopic Dermatitis Drug Provides Sustained Skin Clearance, from 7:44AM ET on Wednesday Sep 25, 2024 by MT Newswires

  7:44AM ET on Wednesday Sep 25, 2024 by MT Newswires
  Companies Mentioned: LLY
  07:44 AM EDT, 09/25/2024 (MT Newswires) -- Eli Lilly (LLY) said Wednesday that results from a long-term study showed that more than 80% of adults and adolescents receiving monthly maintenance dosing of Ebglyss to treat moderate-to-severe atopic derm...

• New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis, from 6:45AM ET on Wednesday Sep 25, 2024 by PR Newswire

  6:45AM ET on Wednesday Sep 25, 2024 by PR Newswire
  Companies Mentioned: LLY

  MonthlyEGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders

  Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year study

• New data show Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis, from 6:45AM ET on Wednesday Sep 25, 2024 by Dow Jones

  6:45AM ET on Wednesday Sep 25, 2024 by Dow Jones
  Companies Mentioned: LLY
  
  EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com